Enabling personalized cancer care

oncobit

Oncobit™ PM for personalized monitoring of melanoma

Imaging data is often difficult to interpret and may not accurately reflect disease progression. Clinical studies have shown that circulating tumor DNA can improve the understanding of patient prognosis and is an appropriate biomarker for monitoring disease recurrence, progression and response to therapy.*

Oncobit™ PM is a digital PCR platform technology consisting of optimized PCR reagents and a proprietary analysis software. This complete solution enables the sensitive detection of specific cancer markers in circulating tumor DNA, as well as an unbiased and automatic report generation, providing a quantitative measure of circulating tumor DNA including the mutant allele frequency.

- **Fully validated with clinical samples according to European guidelines**
- **Unbiased and automatic data analysis and reporting**
- **High accuracy demonstrated with > 1000 patient samples**
- **Precise quantification, e.g. standard error of 0.23% at 1.5% MAF** for BRAFV600E*****
- **High sensitivity, detecting as low as 2 copies per 10,000 wild-type copies (equivalent to 0.02% MAF**)**

Target gene	Single-plex assays for	Limit of Blank (molecules)	Typical Indication
BRAF	V600E/K/R/E2/D	2.8/2.8/1.4/2.7/2.5	Cutaneous melanoma
NRAS	Q61K/L/R	1.8/1.8/1.8	Cutaneous melanoma
GNAQ	Q209P/L	1.8/1.8	Uveal melanoma
GNA11	Q209L	1.8	Uveal melanoma
SF3B1	R625H/C	5.7/7.5	Uveal melanoma

For more information, please contact

Dr. Björn Biedermann, CBO
bjoern.biedermann@oncobit.com
+41 78 256 99 56

www.oncobit.com

* Please find references on the back
** Mutant allele frequency
*** Input material of 18ng cfDNA

CE 2797 IVD

For professional use only. According to the In Vitro Diagnostic Regulation (EU 2017/746).

References

1) Lee, B. et al. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Ann Oncol . 2019 Sep 1;30(9):1472-1478.
2) Tan, L. et al. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 30, 804–814 (2019).
3) Eroglu, Z., et al. Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Cancer. 2023 Jun 1;129(11):1723-1734.
4) Braune, J. et al. Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma. JCO Precis Oncol 4, 20–31 (2020).
5) Tolmeijer, S. H. et al. Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma. Cancers 13, 3913 (2021).
6) Váraljai, R. et al. Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma. JCO Precis. Oncol. 3, PO.18.00229 (2020).
7) Di Nardo, L., et al. The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients. Experimental Dermatology. 2023;32:1785–1793.
8) Lee, J. H. et al. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. JAMA Oncol 4, 717–721 (2018).
9) Zheng, Y. et al. Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis. J. Oncol. 2021, 6660571 (2021).
10) Nathan, P. et al. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021 Sep 23; 385(13):1196-1206
11) Carvajal, R. et al. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nat Med. 2022 Nov;28(11):2364-2373.
12) Hassel, J. et al. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med 2023;389:2256-2266
13) Feng, D. et al. Early ctDNA reduction may identify patients with stable disease and long OS on tebentafusp. Journal of Clinical Oncology Volume 41, Number 16_suppl.
14) Sacco, J. Abstract CT223: Long-term survival follow-up of tebentafusp in previously treated metastatic uveal melanoma (mUM). Cancer Res (2023) 83 (8_Supplement): CT223.